Hypolipidemic Activity of Tetrakis-μ-(trimethylamine-boranecarboxylato)-bis(trimethylamine-carboxyborane)-dicopper(II) in Rodents and Its Effect on Lipid Metabolism

A binuclear copper(II) complex was shown to have potent hypolipidemic activity in rats and mice at low doses, i.e., 2.5–10 mg/kg/d. The agent moderately lowered liver ATP-dependent citrate lyase, acetyl CoA synthetase, and phosphatidate phosphohydrolase activities in vivo. The appetite of the animal...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 1984-07, Vol.73 (7), p.973-977
Main Authors: Hall, I.H., Williams, W.L., Gilbert, Colleen J., McPhail, A.T., Spielvogel, B.F.
Format: Article
Language:English
Subjects:
activity in rodents
Animals
Antihyperlipidemic agents-binuclear copper(II) complex
Antihyperlipidemic agents—binuclear copper(II) complex, activity in rodents, effect on lipid metabolism
Aspirin - analogs & derivatives
Aspirin - chemical synthesis
Aspirin - pharmacology
Bile - metabolism
Binuclear copper(II) complex-antihyperlipidemic activity in rodents
Binuclear copper(II) complex—antihyperlipidemic activity in rodents, effect on lipid metabolism
Biological and medical sciences
Cholesterol - metabolism
Cholesterol-antihyperlipidemic effect of binuclear copper(II) complex
Copper - metabolism
effect on lipid metabolism
Feces - analysis
General pharmacology
Hypolipidemic Agents - chemical synthesis
Hypolipidemic Agents - pharmacology
Intestinal Absorption
Intestine, Small - metabolism
Lipid Metabolism
Lipoproteins - blood
Liver - metabolism
Male
Medical sciences
Mice
Mice, Inbred Strains
Organ Size - drug effects
Pharmacology. Drug treatments
Physicochemical properties. Structure-activity relationships
Rats
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A binuclear copper(II) complex was shown to have potent hypolipidemic activity in rats and mice at low doses, i.e., 2.5–10 mg/kg/d. The agent moderately lowered liver ATP-dependent citrate lyase, acetyl CoA synthetase, and phosphatidate phosphohydrolase activities in vivo. The appetite of the animal was reduced by drug treatment, and orally administered cholesterol absorption from the intestine was markedly lowered. Higher lipid levels were found in the chyme and the feces, indicating accelerated excretion of lipids by the drug, probably via the biliary route. Organs, e.g., liver and small intestine, as well as serum lipoprotein levels, demonstrated lower lipid content after drug administration. Thus, this chemical class of agents may have potential as a hypolipidemic agent in humans.
ISSN:0022-3549
1520-6017
DOI:10.1002/jps.2600730728